Mounjaro overtakes legacy medicines to become India’s top-selling drug
Eli Lilly’s Mounjaro logged ₹1,256 crore in sales in the 12 months to August 2026, growing 502% year-on-year as injectable GLP-1 treatments pull demand from oral diabetes therapies.
What happened
Eli Lilly’s Mounjaro became India’s top-selling pharmaceutical brand, recording ₹1,256 crore in annual sales. Injectable GLP-1 drugs are displacing oral
Key facts
- Mounjaro sales: ₹1,256 crore in the 12 months ending August 2026
- Mounjaro sales growth: 502% year-on-year
- Mounjaro unit growth: 89.4% year-on-year
- August Mounjaro units: down 43.8% month-on-month
- August Mounjaro sales value: up 34.1% month-on-month
- Augmentin sales: ₹957 crore
- Glycomet GP sales: ₹950 crore
- India GLP-1 market: ₹2,333 crore
- India GLP-1 market in August 2022: ₹153 crore
- Tirzepatide share of injectable GLP-1 market by value: nearly 75%
- Tirzepatide share of total GLP-1 market by value: 62%
- Semaglutide share of total GLP-1 market by value: 34%
- Overall pharmaceutical market value growth in August: 10.7%
Why this matters
Eli Lilly’s category-defining momentum makes Indian GLP-1 partnerships, distribution assets, manufacturing capacity, and adjacent metabolic-care platforms increasingly strategic targets.
What to watch
- Mounjaro price reductions, smaller-dose launches or broader insurance/employer reimbursement.
- Novo Nordisk and domestic GLP-1 competitor launches, shortages or capacity expansions.
- Prescription growth for obesity versus type-2 diabetes indications.
- Organized pharmacy cold-chain investment and same-day injectable delivery coverage.
- Sales declines or discounting in DPP-4, SGLT2, sulfonylurea and other oral diabetes therapy segments.
- Regulatory action on obesity prescribing, online dispensing or counterfeit injectable products.
- Build GLP-1 patient journeys spanning prescription fulfilment, cold-chain delivery, refill reminders and clinician-linked adherence support.
- Bundle diabetes and weight-management baskets with protein nutrition, glucose monitoring, diagnostics and dietitian services.
- Segment inventory by metro, affluence and specialist-prescriber density; avoid broad-chain stocking assumptions.
- Prepare substitution and counseling protocols for adverse effects, discontinuation and supply interruptions.
- Track oral diabetes-brand exposure and reallocate pharmacy merchandising toward injectable-support categories.